Bavarian Nordic A/S ( (BVNRY) ) has released its Q4 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its investors.
Bavarian Nordic A/S is a Danish biotechnology company specializing in the development, manufacturing, and commercialization of vaccines for infectious diseases, with a strong focus on travel health and public preparedness. In 2024, Bavarian Nordic reported strong growth in its Travel Health business, achieving a 22% increase in revenue, driven by organic growth and strong brand performance. The company also played a significant role in addressing the mpox outbreak, partnering with global organizations to ensure vaccine availability. Key financial metrics included a revenue of DKK 5,716 million and an EBITDA of DKK 1,603 million, reflecting a solid performance despite a decrease compared to the previous year due to the high mpox vaccine sales in 2023. Looking ahead, Bavarian Nordic plans to launch a chikungunya vaccine in 2025 and continue expanding its portfolio through innovation and strategic partnerships, aiming for sustained growth and improved public health preparedness.